{"id":798065,"date":"2025-01-06T09:20:42","date_gmt":"2025-01-06T14:20:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/renovaro-to-acquire-predictive-oncology-in-all-stock-transaction\/"},"modified":"2025-01-06T09:20:42","modified_gmt":"2025-01-06T14:20:42","slug":"renovaro-to-acquire-predictive-oncology-in-all-stock-transaction","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/renovaro-to-acquire-predictive-oncology-in-all-stock-transaction\/","title":{"rendered":"Renovaro\u00a0to Acquire Predictive Oncology in All-Stock Transaction"},"content":{"rendered":"
\n

\n Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data<\/em>\n <\/p>\n

\n Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul <\/em>\n <\/p>\n

\n Combines Predictive Oncology\u2019s AI-driven multi-omic drug discovery platform with Renovaro\u2019s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery<\/em>\n <\/p>\n

\n Planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes<\/em>\n <\/p>\n

LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) — Renovaro Inc. (NASDAQ: RENB),<\/strong> a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction.<\/p>\n

David Weinstein, Chief Executive Officer of Renovaro, commented, \u201cRenovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring. Predictive Oncology will enhance our capabilities by assisting oncologists with patient specific diagnostic and therapeutic clinical support data. Predictive Oncology\u2019s proprietary AI\/ML platform has been proven to predict tumor-drug response with 92% accuracy which, I believe, will allow us to launch as a decision support platform for medical oncologists in 2025. As importantly, there are strong synergies with Predictive\u2019s small molecule solid tumor drug-tumor response modeling capabilities and Renovaro\u2019s liquid biopsy approach to early cancer detection and monitoring.\u201d<\/p>\n

Raymond Vennare, Chief Executive Officer of Predictive Oncology, added, \u201cWe recognize that by integrating Predictive Oncology\u2019s AI-driven drug discovery platform and vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro\u2019s multi-disciplinary artificial intelligence, multi-omics and multi-modal data expertise, we are opening to door to diagnostic, therapeutic and drug discovery possibilities that we otherwise would never have considered.\u201d<\/p>\n

\n Short-Term Synergies<\/strong>\n <\/p>\n